Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (388)
- Scheduling (national classification system) (171)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
770 result(s) found, displaying 176 to 200
-
Meeting statementsAdvisory Committee on Biologicals meeting statement
-
Meeting statementsAdvisory Committee on Biologicals meeting statement
-
Corporate reportsDocuments released under the FOI Act in the 2022/23 financial year
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 1 September 2023
-
Meeting statementsRead key points of discussion from the meeting 11 of the Medical Devices Consumer Working Group (MDCWG).
-
Scheduling submissionsFind out about public submissions on scheduling matters referred to Advisory Committees meetings, held in March 2022.
-
Scheduling submissionsFind out about public submissions on interim decisions for scheduling matters referred to Advisory Committees meetings, held in March 2022.
-
Scheduling submissionsFind out about public submissions on scheduling matters referred to Advisory Committees meeting, held in March 2023
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 10 August 2023
-
Meeting statementsRead the meeting statement from 8 June 2023 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsThis Cost Recovery Implementation Statement provides information on how the TGA, within the Department of Health, implements and cost recovers its regulatory activities.
-
Corporate reportsMandatory reporting of medical device adverse events by healthcare facilities to the TGA has now commenced, with a period of voluntary reporting in place from March 2025 until 20 March 2026.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsCommunique from the 3rd meeting of the Women's Health Products Working Group (WHPWG), 27 March 2023.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsMeeting statement from the Advisory Committee on Medical Devices (ACMD), 13 April 2023.
-
Corporate reportsThe Access Consortium is offering joint pipeline meetings to pharmaceutical and biotechnology companies.
-
Meeting statementsMeeting statement from meeting 10 of the Medical Devices Consumer Working Group (MDCWG).
-
Scheduling decisions (final)Public notice of final decision to amend (or not amend) the current Poisons Standard - ACMS #40, ACCS #34, Joint ACMS-ACCS #32
-
Scheduling submissionsPublic submissions on interim decisions for scheduling matters referred to the ACMS #40, ACCS #35 and Joint ACMS-ACCS #32 meetings held in November 2022
-
Scheduling decisions (final)On 3 May 2023, the TGA announced the final decision to amend the scheduling of paracetamol in the Poisons Standard.